Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

BACKGROUND: Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism with the anti-inflammatory and anti-fibrotic eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Iskenderian, Andrea, Liu, Nan, Deng, Qingwei, Huang, Yan, Shen, Chuan, Palmieri, Kathleen, Crooker, Robert, Lundberg, Dianna, Kastrapeli, Niksa, Pescatore, Brian, Romashko, Alla, Dumas, John, Comeau, Robert, Norton, Angela, Pan, Jing, Rong, Haojing, Derakhchan, Katayoun, Ehmann, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204036/
https://www.ncbi.nlm.nih.gov/pubmed/30368252
http://dx.doi.org/10.1186/s13395-018-0180-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204036/
https://www.ncbi.nlm.nih.gov/pubmed/30368252
http://dx.doi.org/10.1186/s13395-018-0180-z

Ejemplares similares